A New Drug Class for Heart Failure—Dapagliflozin’s ...
December 1, 2020 - Featured , In the News / Politics By: Adrian Wong, PharmD Candidate c/o 2021 On May 5, 2020, the Food and Drug Administration (FDA) announced its approval for Farxiga® (dapagliflozin) oral tablets to have a new indication: to lower the risk of cardiovascular death and hospitalization for adults with New York Heart Association (NYHA) functional class II-IV heart failure (HF) with reduced… |
|
Antibiotic Resistance: Why It’s Important to Educate ...
December 1, 2020 - Featured , Professional Advice / Opinions By: Natalia Jucha PharmD Candidate c/o 2022 Due to the overuse and misuse of these medications, antibiotics are no longer as effective against their intended pathogens.1 In 2019, the World Health Organization (WHO) released its AWaRE Classification Database which stands for “Access, Watch and Reserve”.2 Clinicians use this database as a guide to appropriately… |
|
Asthma, Alveoli, and Albuterol: A General Overview of A...
December 1, 2020 - Clinical , Featured By: Jeremy Mesias, PharmD Candidate c/o 2022 It starts with a simple cough or a wheeze. Suddenly, it escalates to tightness in the chest. Breathing gets quicker but shallower, making you feel short of breath. These are the most common and recognizable symptoms of an asthma attack. Around the world, nearly 300 million people… |
|
MIS-C: The Impact of COVID-19 on the Pediatric Populati...
December 1, 2020 - Featured , In the News / Politics By: Erica Tonti, PharmD Candidate c/o 2022 Multisystem Inflammatory Syndrome in Children, or MIS-C, is a recent syndrome recognized by the Centers for Disease Control and Prevention (CDC). The emergent outbreak of COVID-19 brought concern as to who would be affected by MIS-C and how severe the impact of the syndrome would be. Children, thought to… |
|
Next Up in the World of Hyperlipidemia: Nexletlol TM...
December 1, 2020 - Featured , In the News / Politics By: Preethi Samuel, Pharm.D. Candidate c/o of 2021 In the United States, at least one person has a heart attack every 40 seconds and 1 of every 5 is silent.1 Heart attacks are commonly a result of atherosclerotic cardiovascular disease (ASCVD). Preceding plaque buildup in arterial walls can potentially lead to a heart attack… |
|
Transition of Care: A New and Emerging Pharmacy Special...
December 1, 2020 - Featured , Professional Advice / Opinions By: Sami Barakat, PharmD. and Natalia Jucha, PharmD. Candidate c/o 2022 Since the publication of the Institute of Medicine report To Err is Human: Building a Safer Health System, there has been a growing movement to improve patient safety. The report revealed that more than 7000 deaths occur annually due to medication errors.1 It… |
|
Vancomycin Monitoring for Serious MRSA Infections in Ad...
December 1, 2020 - Clinical , Featured By: Darien Lee, Pharm D Candidate c/o 2021 Vancomycin, a glycopeptide antibiotic, is one of the most commonly used medications in hospitals. Its widespread use is attributed to its efficacy for the treatment and prevention of bacterial infections caused by gram-positive bacteria. One of its most notable features is its coverage of methicillin-resistant Staphylococcus… |